Loading stock data…
$2.03-0.07 (-3.33%)
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
Nkarta, Inc. in the Healthcare sector is trading at $2.03 with a market capitalization of $211M. Wall Street consensus targets $10.83 (6 analysts), implying a +433.7% move over the next 12 months. The stock is currently near its 52-week low of $1.70, remaining 20.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 5 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$43.13M↓ | -$30.88M↑ | -$30.96M↓ | -$27.29M↓ | -$27.19M |
| Net Income | -$40.37M↓ | -$27.83M↓ | -$27.41M↓ | -$21.71M↑ | -$22.98M |
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK)...